Browsing Tag
HUTCHMED
5 posts
HUTCHMED gets priority review for fanregratinib in FGFR2-positive cholangiocarcinoma in China
HUTCHMED’s fanregratinib gains NDA acceptance with priority review in China. Find out what it means for FGFR2-driven cancers and precision oncology adoption.
HUTCHMED’s ATTC platform and fruquintinib combo data headline 2025 R&D updates
Find out how HUTCHMED’s new ATTC platform and strong late-stage trial results could reshape its cancer drug pipeline and investor outlook today.
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
Hutchmed secures priority review in China for ORPATHYS and TAGRISSO combination therapy
Hutchmed (China) Limited has achieved a significant milestone with the acceptance of its New Drug Application (NDA) by…
HUTCHMED to sell non-core JV for $608m to focus on oncology
HUTCHMED (China) Limited has taken a bold step in streamlining its operations by divesting its 45% equity interest…